By: Kerri Fitzgerald
The phase 3 MagnetisMM-6 study showed a manageable safety profile and high response rates in transplant-ineligible, newly diagnosed multiple myeloma (MM) patients treated with the combination of elranatamab, daratumumab, and lenalidomide.
Part one of the study was presented by Hang Quach, MBBS(Hons), of St. Vincent’s Hospital in Melbourne, Australia, as part of the SOHO 2025 Annual Meeting.
In the dose level G cohort, 34 patients (median age, 75 years) received a subcutaneous (SC) elranatamab priming regimen followed by 76 mg every four weeks, SC daratumumab 1,800 mg, and oral lenalidomide 25 mg.
Most patients were White (86.5%), 24.3% had 50% or more baseline bone marrow plasma cells, and 24.3% were frail according to the International Myeloma Working Group frailty score.
As of December 23, 2024, the median follow-up was 4.6 months, and 33 patients were still receiving treatment.
Almost all patients (97.3%) experienced treatment-emergent adverse events, many of whom experienced hematologic adverse events (78.4%) and infections (64.9%). Cytokine release syndrome occurred in almost two-thirds (62.2%), and one case of grade 2 immune effector cell-associated neurotoxicity syndrome was reported.
Thirty-six patients responded to treatment, with an overall response rate of 91.9% and a very good partial response or better rate of 81.1%.
Enrollment in other dose levels of this trial is ongoing.
Reference
Quach H, Pour L, Grosicki S, et al. Elranatamab (ELRA) in combination with daratumumab and lenalidomide in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: initial results from MagnetisMM-6 part 1. Abstract #MM-1037. Presented at the Society of Hematologic Oncology 2025 Annual Meeting; September 3-6, 2025; Houston, Texas.
Visit the SOHO 2025 meeting news page for more coverage from the meeting.
